Botanix Provides Sofdra Launch Update

Open PDF
Stock Botanix Pharmaceuticals Ltd (BOT.ASX)
Release Time 8 Jul 2025, 8:27 a.m.
Price Sensitive Yes
 Botanix Provides Sofdra Launch Update
Key Points
  • Sofdra has shown strong demand and performance in line with recent dermatology launches
  • Gross sales of approximately $25 million AUD since January 2025
  • Over 16,000 prescriptions filled across 6,700 patients since launch
Full Summary

Botanix Pharmaceuticals Ltd (ASX: BOT) has provided an update on the launch of its lead product Sofdra (sofpironium) topical gel, 12.45%, showing strong demand and performance in line with recent successful dermatology launches. The company has reported gross sales of approximately $25 million AUD since January 2025, with increases month over month. Sofdra has achieved important milestones, including expanding its prescriber base to over 2,300 unique prescribers in June 2025, and having over 16,000 prescriptions filled across 6,700 patients from launch to 30 June 2025. The refill rate for Sofdra has exceeded the industry average, with patients starting the medication in February 2025 already receiving 3.4 fills on average, compared to the industry average of 2 fills per year. Botanix is making strategic investments to further accelerate Sofdra's growth, including expanding the sales team and increasing the number of territories. The company is also maintaining a digital presence and implementing a speaker program and medical education initiatives to support the launch. Botanix Executive Chairman Vince Ippolito expressed his satisfaction with Sofdra's performance, stating that the launch trajectory is trending positively and the company expects continued growth.

Guidance

Botanix reported gross sales of approximately $25 million AUD for Sofdra since January 2025, with increases month over month. The company is targeting a 30-40% gross to net (GTN) yield for Sofdra, which is tracking with top US dermatology companies.

Outlook

Botanix is making strategic investments to further accelerate Sofdra's growth, including expanding the sales team and increasing the number of territories. The company expects continued growth for Sofdra.